1. Alkermes. (2010, October 12). Alkermes Announces FDA Approval of VIVITROL® for Prevention of Relapse to Opioid Dependence. https://investor.alkermes.com/node/9066/pdf.
2. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians;Booty;J. Subst. Use Addict. Treat.,2023
3. J.A.Holstein, J.F.Gubrium, Charmaz K., 2003 Qualitative interviewing and grounded theory analysis. In Inside interviewing: New lenses, new concerns311–30Sage Publications,Thousand Oaks, CAJ.A.Holstein, J.F.Gubrium, Charmaz K., 2003 Qualitative interviewing and grounded theory analysis. In Inside interviewing: New lenses, new concerns311–30Sage Publications,Thousand Oaks, CA.
4. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder;Cioe;J. Subst. Abus. Treat.,2020
5. Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic;Friedman;JAMA Psychiatry,2022